Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA ...
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience ...
PHILADELPHIA, June 29, 2021 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines ...
Central nervous system (CNS) clinical trials are among the most scientifically complex and operationally demanding in life sciences. The need to evaluate nuanced cognitive, behavioral, and emotional ...
Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC). Validation of the association of RECIST ...
Service ensures that clinicians are properly qualified, consistently trained and monitored throughout the life of a trialMAIDENHEAD, England--(BUSINESS WIRE)--RWS (RWS.L), a global AI solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results